Dosimetric comparison of VitalBeam® and HalcyonTM 2.0 for hypofractionated VMAT with simultaneous integrated boost treatment of early-stage left-sided breast cancer.

Eunbin JuEun Jeong HeoChun Gun ParkMinseok KimKwang Hyeon KimJang Bo ShimYoung Je ParkNam Kwon LeeChul Yong KimSuk Lee

Published in: Journal of applied clinical medical physics (2021)

DL-MLC plans were found to improve OAR sparing. In particular, when treating left-sided breast cancer via DL-MLC plans, the risk of heart toxicity is expected to be reduced.

Keyphrases

early stage
radiation therapy
health insurance
heart failure
small cell lung cancer
sentinel lymph node
breast cancer risk
lymph node
combination therapy
young adults
clinical evaluation
smoking cessation